NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer

Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m C) in cervic...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 23; no. 1; pp. 139 - 16
Main Authors Yu, Min, Ni, Mengdong, Xu, Fei, Liu, Chaohua, Chen, Lihua, Li, Jiana, Xia, Siyu, Diao, Yixin, Chen, Jiaxin, Zhu, Jun, Wu, Xiaohua, Tang, Min, Li, Jiajia, Ke, Guihao
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.07.2024
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m C) in cervical cancer radiosensitivity. The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m C sequencing, mRNA sequencing, and RNA immunoprecipitation. We found a higher abundance of m C modification in resistant CC samples, and NSUN6 was the essential m C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m C modification of NDRG1 mRNA, and the m C reader ALYREF bound explicitly to the m C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Aberrant m C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.
AbstractList Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m C) in cervical cancer radiosensitivity. The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m C sequencing, mRNA sequencing, and RNA immunoprecipitation. We found a higher abundance of m C modification in resistant CC samples, and NSUN6 was the essential m C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m C modification of NDRG1 mRNA, and the m C reader ALYREF bound explicitly to the m C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Aberrant m C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.
Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m.sup.5C) in cervical cancer radiosensitivity. The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m.sup.5C sequencing, mRNA sequencing, and RNA immunoprecipitation. We found a higher abundance of m.sup.5C modification in resistant CC samples, and NSUN6 was the essential m.sup.5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m.sup.5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m.sup.5C modification of NDRG1 mRNA, and the m.sup.5C reader ALYREF bound explicitly to the m.sup.5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Aberrant m.sup.5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m.sup.5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.
Abstract Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity. Methods The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation. Results We found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Conclusions Aberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.
Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity.BACKGROUNDRadioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity.The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation.METHODSThe abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation.We found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.RESULTSWe found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.Aberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.CONCLUSIONSAberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.
Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m.sup.5C) in cervical cancer radiosensitivity. Methods The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m.sup.5C sequencing, mRNA sequencing, and RNA immunoprecipitation. Results We found a higher abundance of m.sup.5C modification in resistant CC samples, and NSUN6 was the essential m.sup.5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m.sup.5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m.sup.5C modification of NDRG1 mRNA, and the m.sup.5C reader ALYREF bound explicitly to the m.sup.5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Conclusions Aberrant m.sup.5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m.sup.5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Keywords: Cervical cancer, Radioresistance, m.sup.5C modification, NSUN6, 3D bioprinted patient-derived organoid
ArticleNumber 139
Audience Academic
Author Ke, Guihao
Chen, Jiaxin
Li, Jiajia
Chen, Lihua
Tang, Min
Xia, Siyu
Wu, Xiaohua
Yu, Min
Diao, Yixin
Li, Jiana
Zhu, Jun
Liu, Chaohua
Ni, Mengdong
Xu, Fei
Author_xml – sequence: 1
  givenname: Min
  surname: Yu
  fullname: Yu, Min
– sequence: 2
  givenname: Mengdong
  surname: Ni
  fullname: Ni, Mengdong
– sequence: 3
  givenname: Fei
  surname: Xu
  fullname: Xu, Fei
– sequence: 4
  givenname: Chaohua
  surname: Liu
  fullname: Liu, Chaohua
– sequence: 5
  givenname: Lihua
  surname: Chen
  fullname: Chen, Lihua
– sequence: 6
  givenname: Jiana
  surname: Li
  fullname: Li, Jiana
– sequence: 7
  givenname: Siyu
  surname: Xia
  fullname: Xia, Siyu
– sequence: 8
  givenname: Yixin
  surname: Diao
  fullname: Diao, Yixin
– sequence: 9
  givenname: Jiaxin
  surname: Chen
  fullname: Chen, Jiaxin
– sequence: 10
  givenname: Jun
  surname: Zhu
  fullname: Zhu, Jun
– sequence: 11
  givenname: Xiaohua
  surname: Wu
  fullname: Wu, Xiaohua
– sequence: 12
  givenname: Min
  surname: Tang
  fullname: Tang, Min
– sequence: 13
  givenname: Jiajia
  surname: Li
  fullname: Li, Jiajia
– sequence: 14
  givenname: Guihao
  surname: Ke
  fullname: Ke, Guihao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38970106$$D View this record in MEDLINE/PubMed
BookMark eNp9kt9rFDEQxxep2B_6D_ggC774sjWzm2SzT3JUrYVyQrXPIZlNrim7mzPJFe6_N3vXSk9EQsgw-c6HSeZ7WhxNfjJF8RbIOYDgHyPUHW0qUtO8CWNV_aI4AdryirJOHD2Lj4vTGO8JgVa09FVx3IiuJUD4SWGXP26XvBpN71QyfclymO62A26Tj24y5eh7Zx2q5PxUelsuP99cQjneLBflOvjRJxPLoHrng4kuJjWhKd1UogkPuWoocc6E18VLq4Zo3jyeZ8Xt1y8_L75V198vry4W1xWyhqcKtNWaWd21VGuluRDcgO6JVtRaRojgCniHjCMVxCrosVWUakE6tEYxaM6Kqz239-peroMbVdhKr5zcJXxYSRWSw8FIJBaQW1AENRUMOsuQCUrbzrZNq21mfdqz1hud_wfNlIIaDqCHN5O7kyv_IAHqmuWBZMKHR0LwvzYmJjm6iGYY1GT8JsqGtLwWXECdpe_30pXKvbnJ-ozEWS4XgpCaA2lm1fk_VHn1ZnSY3WFdzh8UvHv-hj_NPxkgC8RegMHHGIyV6NJu2JnsBglEzl6Te6_J7DW585qc2fVfpU_0_xT9BqXO1jE
CitedBy_id crossref_primary_10_3390_biomedicines12112533
crossref_primary_10_1016_j_molmed_2024_11_001
crossref_primary_10_1007_s10565_024_09924_y
crossref_primary_10_1002_mc_23857
crossref_primary_10_1038_s41698_024_00737_0
Cites_doi 10.1038/s41556-019-0361-y
10.1038/cr.2017.55
10.1093/nar/gkx473
10.1073/pnas.1314469111
10.1182/blood.2022015752
10.1016/j.stem.2019.10.010
10.1186/s12943-021-01340-8
10.1038/s41598-023-45144-w
10.1038/s41416-023-02542-1
10.1038/s41388-021-01735-3
10.1056/NEJMra1805035
10.1038/s41388-023-02707-5
10.1038/s41392-020-00450-x
10.1186/s13046-018-0758-7
10.1073/pnas.2116251119
10.1093/nar/gks144
10.1038/s41392-023-01639-6
10.1038/s41392-020-0150-x
10.1016/j.cmet.2023.07.009
10.1038/s41418-023-01223-z
10.1159/000535479
10.1001/jama.298.19.2289
10.1093/nar/gkaa1193
10.1124/pharmrev.122.000795
10.1186/s12943-023-01780-4
10.1016/j.drup.2023.101033
10.1186/s12943-023-01801-2
10.1002/ctm2.545
10.1016/j.redox.2023.102975
10.1002/ctm2.1466
10.1002/mco2.55
10.1093/nsr/nwaa273
10.1038/s41388-021-01978-0
10.1002/advs.202003897
10.1038/s41388-020-1250-3
10.1016/j.ccell.2023.04.019
10.1016/j.ymthe.2023.07.018
10.7150/ijbs.79205
10.1016/j.bbcan.2023.188871
10.1158/1078-0432.CCR-18-3590
10.1016/j.ebiom
10.1016/S0140-6736(18)32470-X
10.1186/s13046-019-1268-y
10.1158/0008-5472.CAN-21-0871
10.1186/s12943-023-01782-2
10.1111/jcmm.17826
10.1038/cr.2017.73
10.1038/s41580-019-0168-5
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
The Author(s) 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: The Author(s) 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12943-024-02055-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 16
ExternalDocumentID oai_doaj_org_article_c0f1c6f1a0cb48519f5c584479f737bf
PMC11225205
A800261032
38970106
10_1186_s12943_024_02055_2
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 82272898
– fundername: Science and Technology Commission of Shanghai Municipality
  grantid: 22YF1409100
– fundername: National Natural Science Foundation of China
  grantid: 82272682
– fundername: National Natural Science Foundation of China
  grantid: 82303661
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c536t-1bfbb5fb974bbab6886e1bd0ba4ff50086a169c56c480fa1dc7a44b809cfea513
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:31:44 EDT 2025
Thu Aug 21 18:32:24 EDT 2025
Mon Jul 21 09:20:31 EDT 2025
Tue Jun 17 22:08:47 EDT 2025
Tue Jun 10 21:02:56 EDT 2025
Mon Jul 21 06:04:06 EDT 2025
Thu Apr 24 23:01:37 EDT 2025
Tue Jul 01 01:01:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Radioresistance
3D bioprinted patient-derived organoid
NSUN6
Cervical cancer
m5C modification
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c536t-1bfbb5fb974bbab6886e1bd0ba4ff50086a169c56c480fa1dc7a44b809cfea513
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/c0f1c6f1a0cb48519f5c584479f737bf
PMID 38970106
PQID 3076286812
PQPubID 23479
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_c0f1c6f1a0cb48519f5c584479f737bf
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11225205
proquest_miscellaneous_3076286812
gale_infotracmisc_A800261032
gale_infotracacademiconefile_A800261032
pubmed_primary_38970106
crossref_citationtrail_10_1186_s12943_024_02055_2
crossref_primary_10_1186_s12943_024_02055_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-05
PublicationDateYYYYMMDD 2024-07-05
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References SE Bates (2055_CR10) 2020; 383
N Gabriel (2055_CR8) 2022; 82
S Javed (2055_CR48) 2024; 130
PA Cohen (2055_CR1) 2019; 393
X Chen (2055_CR13) 2019; 21
S-J Chen (2055_CR41) 2024; 69
D Yan (2055_CR42) 2023; 27
W Jiang (2055_CR2) 2024; 72
R-J Liu (2055_CR22) 2017; 45
M Ni (2055_CR29) 2021; 40
M Buttarelli (2055_CR46) 2019; 38
JK Schwarz (2055_CR3) 2007; 298
F Xu (2055_CR24) 2021; 20
H Zhuang (2055_CR7) 2023; 22
C Macedo-Silva (2055_CR9) 2023; 8
D Frank (2055_CR33) 2023; 142
YP Liu (2055_CR6) 2021; 2
Z Deng (2055_CR30) 2023; 75
D Dominissini (2055_CR18) 2017; 27
J Liu (2055_CR15) 2021; 8
Z Lu (2055_CR43) 2024; 33
Z Liu (2055_CR35) 2021; 11
S Zaccara (2055_CR31) 2019; 20
X Yang (2055_CR16) 2017; 27
T Selmi (2055_CR14) 2021; 49
Y Chen (2055_CR21) 2023; 19
H Yang (2055_CR37) 2022; 119
X Zhao (2055_CR45) 2023; 1878
M Weiler (2055_CR32) 2014; 111
ZN Abbas (2055_CR27) 2023; 13
CA Pasch (2055_CR25) 2019; 25
L Tang (2055_CR4) 2018; 37
R-X Huang (2055_CR28) 2020; 5
X Sun (2055_CR36) 2023; 31
P Li (2055_CR38) 2023; 13
X Jiang (2055_CR11) 2021; 6
Y Yao (2055_CR26) 2020; 26
M-KN Hutchinson (2055_CR23) 2020; 39
R Yang (2055_CR44) 2021; 63
L Wang (2055_CR34) 2023; 41
Y Wu (2055_CR5) 2023; 22
Y Wang (2055_CR17) 2023; 22
Y Zhang (2055_CR40) 2023; 30
JE Squires (2055_CR12) 2012; 40
T Chen (2055_CR39) 2023; 35
J Su (2055_CR20) 2021; 40
K Liu (2055_CR19) 2023; 42
Y Zhao (2055_CR47) 2021; 8
References_xml – volume: 21
  start-page: 978
  issue: 8
  year: 2019
  ident: 2055_CR13
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-019-0361-y
– volume: 27
  start-page: 606
  issue: 5
  year: 2017
  ident: 2055_CR16
  publication-title: Cell Res
  doi: 10.1038/cr.2017.55
– volume: 45
  start-page: 6684
  issue: 11
  year: 2017
  ident: 2055_CR22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx473
– volume: 111
  start-page: 409
  issue: 1
  year: 2014
  ident: 2055_CR32
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1314469111
– volume: 142
  start-page: 2175
  issue: 25
  year: 2023
  ident: 2055_CR33
  publication-title: Blood
  doi: 10.1182/blood.2022015752
– volume: 26
  start-page: 17
  issue: 1
  year: 2020
  ident: 2055_CR26
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2019.10.010
– volume: 20
  start-page: 1
  year: 2021
  ident: 2055_CR24
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01340-8
– volume: 13
  start-page: 18380
  issue: 1
  year: 2023
  ident: 2055_CR27
  publication-title: Sci Rep
  doi: 10.1038/s41598-023-45144-w
– volume: 130
  start-page: 467
  issue: 3
  year: 2024
  ident: 2055_CR48
  publication-title: Br J Cancer
  doi: 10.1038/s41416-023-02542-1
– volume: 40
  start-page: 2711
  issue: 15
  year: 2021
  ident: 2055_CR29
  publication-title: Oncogene
  doi: 10.1038/s41388-021-01735-3
– volume: 383
  start-page: 650
  issue: 7
  year: 2020
  ident: 2055_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1805035
– volume: 42
  start-page: 1980
  issue: 24
  year: 2023
  ident: 2055_CR19
  publication-title: Oncogene
  doi: 10.1038/s41388-023-02707-5
– volume: 6
  start-page: 74
  issue: 1
  year: 2021
  ident: 2055_CR11
  publication-title: Signal Transduct Target Therapy
  doi: 10.1038/s41392-020-00450-x
– volume: 37
  start-page: 1
  year: 2018
  ident: 2055_CR4
  publication-title: J Experimental Clin Cancer Res
  doi: 10.1186/s13046-018-0758-7
– volume: 119
  start-page: e2116251119
  issue: 12
  year: 2022
  ident: 2055_CR37
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.2116251119
– volume: 40
  start-page: 5023
  issue: 11
  year: 2012
  ident: 2055_CR12
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gks144
– volume: 8
  start-page: 395
  issue: 1
  year: 2023
  ident: 2055_CR9
  publication-title: Signal Transduct Target Therapy
  doi: 10.1038/s41392-023-01639-6
– volume: 5
  start-page: 60
  issue: 1
  year: 2020
  ident: 2055_CR28
  publication-title: Signal Transduct Target Therapy
  doi: 10.1038/s41392-020-0150-x
– volume: 35
  start-page: 1782
  issue: 10
  year: 2023
  ident: 2055_CR39
  publication-title: Cell Metabol
  doi: 10.1016/j.cmet.2023.07.009
– volume: 30
  start-page: 2462
  issue: 12
  year: 2023
  ident: 2055_CR40
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-023-01223-z
– volume: 33
  start-page: 56
  issue: 1
  year: 2024
  ident: 2055_CR43
  publication-title: Med Principles Pract
  doi: 10.1159/000535479
– volume: 298
  start-page: 2289
  issue: 19
  year: 2007
  ident: 2055_CR3
  publication-title: JAMA
  doi: 10.1001/jama.298.19.2289
– volume: 49
  start-page: 1006
  issue: 2
  year: 2021
  ident: 2055_CR14
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa1193
– volume: 75
  start-page: 1007
  issue: 5
  year: 2023
  ident: 2055_CR30
  publication-title: Pharmacol Rev
  doi: 10.1124/pharmrev.122.000795
– volume: 22
  start-page: 81
  issue: 1
  year: 2023
  ident: 2055_CR17
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01780-4
– volume: 72
  start-page: 101033
  year: 2024
  ident: 2055_CR2
  publication-title: Drug Resist Updates
  doi: 10.1016/j.drup.2023.101033
– volume: 22
  start-page: 96
  issue: 1
  year: 2023
  ident: 2055_CR5
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01801-2
– volume: 11
  start-page: e545
  issue: 9
  year: 2021
  ident: 2055_CR35
  publication-title: Clin Translational Med
  doi: 10.1002/ctm2.545
– volume: 69
  start-page: 102975
  year: 2024
  ident: 2055_CR41
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2023.102975
– volume: 13
  start-page: e1466
  issue: 11
  year: 2023
  ident: 2055_CR38
  publication-title: Clin Translational Med
  doi: 10.1002/ctm2.1466
– volume: 2
  start-page: 315
  issue: 3
  year: 2021
  ident: 2055_CR6
  publication-title: MedComm
  doi: 10.1002/mco2.55
– volume: 8
  start-page: nwaa273
  issue: 6
  year: 2021
  ident: 2055_CR15
  publication-title: Natl Sci Rev
  doi: 10.1093/nsr/nwaa273
– volume: 40
  start-page: 5814
  issue: 39
  year: 2021
  ident: 2055_CR20
  publication-title: Oncogene
  doi: 10.1038/s41388-021-01978-0
– volume: 8
  start-page: 2003897
  issue: 11
  year: 2021
  ident: 2055_CR47
  publication-title: Adv Sci
  doi: 10.1002/advs.202003897
– volume: 39
  start-page: 3638
  issue: 18
  year: 2020
  ident: 2055_CR23
  publication-title: Oncogene
  doi: 10.1038/s41388-020-1250-3
– volume: 41
  start-page: 1294
  issue: 7
  year: 2023
  ident: 2055_CR34
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.04.019
– volume: 31
  start-page: 2633
  issue: 9
  year: 2023
  ident: 2055_CR36
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2023.07.018
– volume: 19
  start-page: 691
  issue: 2
  year: 2023
  ident: 2055_CR21
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.79205
– volume: 1878
  start-page: 188871
  issue: 3
  year: 2023
  ident: 2055_CR45
  publication-title: Biochim et Biophys Acta (BBA)-Reviews Cancer
  doi: 10.1016/j.bbcan.2023.188871
– volume: 25
  start-page: 5376
  issue: 17
  year: 2019
  ident: 2055_CR25
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-3590
– volume: 63
  start-page: 103195
  year: 2021
  ident: 2055_CR44
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom
– volume: 393
  start-page: 169
  issue: 10167
  year: 2019
  ident: 2055_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)32470-X
– volume: 38
  start-page: 1
  year: 2019
  ident: 2055_CR46
  publication-title: J Experimental Clin Cancer Res
  doi: 10.1186/s13046-019-1268-y
– volume: 82
  start-page: 2019
  issue: 10
  year: 2022
  ident: 2055_CR8
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-21-0871
– volume: 22
  start-page: 91
  issue: 1
  year: 2023
  ident: 2055_CR7
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01782-2
– volume: 27
  start-page: 2398
  issue: 16
  year: 2023
  ident: 2055_CR42
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.17826
– volume: 27
  start-page: 717
  issue: 6
  year: 2017
  ident: 2055_CR18
  publication-title: Cell Res
  doi: 10.1038/cr.2017.73
– volume: 20
  start-page: 608
  issue: 10
  year: 2019
  ident: 2055_CR31
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-019-0168-5
SSID ssj0017874
Score 2.499237
Snippet Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory...
Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a...
Abstract Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 139
SubjectTerms 3D bioprinted patient-derived organoid
5-Methylcytosine - analogs & derivatives
5-Methylcytosine - metabolism
Analysis
Animals
Cell Cycle Proteins - genetics
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Cervical cancer
DNA
Drug resistance
Ethylenediaminetetraacetic acid
Female
Gene Expression Regulation, Neoplastic
Genes
Humans
Intracellular Signaling Peptides and Proteins - genetics
Intracellular Signaling Peptides and Proteins - metabolism
Liquid chromatography
m5C modification
Mass spectrometry
Messenger RNA
Methyltransferases - genetics
Methyltransferases - metabolism
Mice
NSUN6
Prognosis
Radiation
Radiation Tolerance - genetics
Radioresistance
RNA sequencing
RNA, Messenger - genetics
RNA, Messenger - metabolism
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - metabolism
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - radiotherapy
Xenograft Model Antitumor Assays
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl0NJLadOX27SoUOihmFheSZaP20caCvEh7UJuQiNLdCGxw-7msP--M7J3WVNoLz34Ysl4pBnNfIPmwdh7E6GsY6iRA1XIJUCVA7rLudSqFs5FbQIlOF80-nwhv1-pq4NWXxQTNpQHHjbu1BdReB2FKzxIhAd1VB6NpqzqWM0qiKR90ebtnKnx_gDFUO5SZIw-XaNVk3RfKfEplMrLiRlK1fr_1MkHRmkaMHlggc4es0cjdOTzgeQn7F7ojtn9oZnk9pg9uBivyZ-y2PxYNDpPWSGIKLnKqVH09tpvNz3FufObvqUQocQV3kfefLn8JvjNZTPntyk-L6z5yrXLHp1xApgoGXzZcZ8UC9Lg6c3qGVucff35-TwfGyrkXs30JhcQAVQE9CEAHGhjdBDQFuBkjIq8Gyd07ZX20hTRidZXTkowRe1jcErMnrOjru_CS8YNxLKCVgTEMzL6ForWCfCEltroKpExsdtf68dq49T04tomr8NoO_DEIk9s4oktM_Zx_83tUGvjr7M_Edv2M6lOdnqB0mNH6bH_kp6MfSCmWzrNSJ53Y1ICLpLqYtm5SU5qMcPfnUxm4in0k-F3O7GxNESha13o79YWlSil_yKQytiLQYz2NCNarMgpz5iZCNhkUdORbvkrFQFHnFwq3IlX_2MbXrOHZTocVV6oE3a0Wd2FNwi2NvA2navfUUsmYg
  priority: 102
  providerName: Directory of Open Access Journals
Title NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/38970106
https://www.proquest.com/docview/3076286812
https://pubmed.ncbi.nlm.nih.gov/PMC11225205
https://doaj.org/article/c0f1c6f1a0cb48519f5c584479f737bf
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfGJhAvCAaMwKiChMQDCsStv_KAUAcbE1IjVKjUN8t2bKjUJaPtJPrfc-emZRETEg95iZ3E9t35fhffByEvVbD9IvgCKCB9xqyVmQVzOWOCF9SYIJTHAOdRKc4n7POUT_fIttxRu4DLG007rCc1Wczf_Pq5fg8C_y4KvBJvl6CzGJ5GMrhyzjPYkg9AM0kU1BH7c6oAzBlPmRkOhhdqG0Rz4zs6iirm8_97176mtrouldd01Nl9cq8Fl-lwww0PyJ6vD8ntTbnJ9SG5M2oP0h-SUH6dlCKLcSOAOVOeYSnp9dytVw16wqcXTYVORJFuaRPS8uP4E00vxuUwvYwefH6ZLkw1a8BcRwgKvJPO6tTFrQfG4PDO4hGZnJ1--3CetSUXMscHYpVRG6zlwYKVYa2xQinhqa1ya1gIHO0fQ0XhuHBM5cHQyknDmFV54YI3nA4ek_26qf0Tkiob-tJW1APiYcFVNq8MtQ7xVBWMpAmh2_XVrs1HjmUx5jraJUroDU000ERHmuh-Ql7vnrncZOP4Z-8TJNuuJ2bSjjeaxXfdCqZ2eaBOBGpyZxnAzyJwB6CMySLIgbQhIa-Q6Bo5EIbnTBu2AJPEzFl6qKIZmw_gc8edniCnrtP8Yss2GpvQua32zdVSwzaLAcIAtRJytGGj3ZgBT0o02xOiOgzWmVS3pZ79iGnCAUn3OazE0_9atGfkbj9Kgcxyfkz2V4sr_xxw18r2yC05lT1ycHJafhn34t-LXhSw33S7Kfs
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NSUN6-mediated+5-methylcytosine+modification+of+NDRG1+mRNA+promotes+radioresistance+in+cervical+cancer&rft.jtitle=Molecular+cancer&rft.au=Yu%2C+Min&rft.au=Ni%2C+Mengdong&rft.au=Xu%2C+Fei&rft.au=Liu%2C+Chaohua&rft.date=2024-07-05&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-024-02055-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_024_02055_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon